The “From Basic to Clinical” strategy for directly translating basic research成果 into clinical applications
First written in FY2023. 2 of 3 entries say "Restated". Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025RestatedAnnual report
「The “From Basic to Clinical” strategy of directly applying the results of cutting-edge basic research cultivated over many years at Keio University School of Medicine to business activities.」
The company continues its strategy of directly applying Keio University basic research results to business activities. - FY2024RestatedAnnual report
「We will advance both the “From Basic to Clinical” strategy of directly applying the results of cutting-edge basic research cultivated over many years at Keio University School of Medicine to business activities and the “From Rare to Common” strategy of connecting research and development for intractable rare diseases with research and development for common diseases affecting larger patient populations.」
The company continues its From Basic to Clinical strategy of commercializing university basic research results. - FY2023First statedAnnual report
「The “From Basic to Clinical” strategy of directly applying the results of cutting-edge basic research cultivated over many years at Keio University School of Medicine to business activities.」
The company first explicitly stated its strategy of directly applying accumulated university basic research results to business activities.